FDA Approves Revolutionary Pill for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has approved Rasonque, a new tablet for advanced pancreatic cancer treatment, manufactured by Revolution Medicines in California. This once-daily pill is an inhibitor targeting multiple forms of the RAS protein, a key driver of tumor growth in pancreatic cancer.

In an early announcement, the FDA described Rasonque as a ‘new treatment option for patients with advanced pancreatic cancer,’ stressing that approval was granted ahead of the anticipated review date. Acting FDA Commissioner Kyle Diamantas expressed pride in the FDA scientists, whose swift and thorough evaluation enabled this advancement.

Rasonque is intended for adults with metastatic pancreatic cancer who have not had success with prior treatments or are unable to undergo specific combination drug therapies. Pancreatic adenocarcinoma, accounting for nearly 95% of approximately 67,000 annual pancreatic cancer cases in the U.S., poses significant challenges. Although representing only 3.2% of all cancer diagnoses, its late detection and rapid spread result in high mortality rates.

A pivotal randomized, open-label trial with 500 participants demonstrated remarkable outcomes. Patients receiving Rasonque showed a median overall survival of 13.2 months, which is nearly double the 6.7-month survival rate in the control group undergoing standard chemotherapy.

The FDA’s approval process was expedited through priority review, orphan drug status, and breakthrough therapy designation, facilitated by the National Priority Voucher pilot program to ensure prompt access to vital public health treatments. Prior to official approval, a ‘safe to proceed’ letter in May authorized expanded drug access.

‘This drug showed unprecedented results in an area of high unmet need,’ remarked Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.

Clinical trials reported common side effects such as rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and bleeding.

‘Today’s landmark approval is the most significant advance we have seen in the fight against pancreatic cancer, a devastating disease,’ stated Anna Berkenblit, M.D., chief scientific and medical officer of the Pancreatic Cancer Action Network (PanCAN).

Berkenblit expressed optimism that Rasonque could transform pancreatic cancer treatment, offering patients longer life, enhanced quality of living, and hope for further research breakthroughs.